The upcoming drugs CagriSema and retatrutide target multiple gut hormones and could cause twice as much weight loss than ...

Feb 11 (Reuters) - Novo Nordisk said on Wednesday it plans to launch its weight-loss pill Wegovy in vials. "We are exploring ...

After Bonnie had part of her thyroid removed, weight gain accompanied the aftermath of the procedure. The Connecticut ...

Men no longer view aesthetic treatments as vanity but as optimization, similar to fitness, grooming or skincare,” one ...

We decided to exit the Oracle position and book a short-term tax loss, spreading the capital across several of the ...

Eli Lilly's full-year guidance comes in stark contrast to the outlook of Novo Nordisk, which warned it sees sales and profit ...

Eli Lilly is priced for perfection thanks to its GLP-1 drugs, while Wall Street seems to have forgotten about these two ...

Joe Budden discusses using Zepbound, fitness changes, and health awareness during an appearance on 'Club Shay Shay.' ...

The Danish drugmaker kicked off 2026 with its explosive obesity pill launch, but recent challenges have centered around protecting its market share.

Late last year, Lilly was the first pharmaceutical stock to reach a $1 trillion valuation.

Mounjaro and Zepbound generated a combined $11.7 billion in sales for the company in its most recent quarter.

Compare Zepbound and Wegovy to understand how one hormone vs two impacts weight loss, appetite control, side effects, and ...